[Efficacy of omalizumab in patients with severe asthma using the asthma health questionnaire and asthma control test].
CONCLUSION: Although treatment with omalizumab could not improve lung function, AHQ and ACT during the 16-week study period had significantly improved compared to baseline. Omalizumab significantly reduced the number of emergency visits and dosages of methylprednisolone.
PMID: 25634459 [PubMed - in process]
Source: Allergology International - Category: Allergy & Immunology Tags: Arerugi Source Type: research
More News: Allergy & Immunology | Asthma | Emergency Medicine | Methylprednisolone | Pulmonary Function Testing | Respiratory Medicine | Study | Xolair